Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
Hyperbaric treatment schedules has shown success over the years. IWR is not without risk and should be undertaken with certain precautions. IWR would only be suitable for an organised and disciplined group of divers with suitable equipment and practical training in the procedure. Treatment of decompression sickness, arterial gas embolism, and other medical applications. The type of chamber which can be used depends on the maximum pressure required for the schedule, and what gases are used for treatment. Most treatment protocols for diving injuries require an attendant in the chamber, and a medical lock to transfer medical supplies into the chamber while under